Search Instructions:
* Filter the ENTIRE resource library: Choose a OR a to sort all resources.
* Choose Search Items : to filter one collection or perform complex queries.
* Choose Browse by Topic to search by one or more Topics.
Browse Items (106 total)
-
Creator: the PlasmAr Study Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-18
Description: Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes. Minimal data are available from adequately powered randomized, controlled… -
Creator: the Fundación INFANT–COVID-19 Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-18
Description: Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive. Among them, convalescent plasma administered to hospitalized patients has been unsuccessful, perhaps because antibodies should be administered earlier… -
Creator: The RECOVERY Collaborative Group
Subject: Research
Item Type: Publication
Date Last Updated: 2021-02-02
Description: Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.A response to this article was… -
Creator: NETEC
Subject: Treatment & Care
Item Type: Guide
Date Last Updated: 2020-12-10
Description: This printable flyer infographic discusses mAb for COVID-19. Monoclonal antibody therapeutics (mAb) are one of the first available medical countermeasure therapeutics for mild-to-moderate COVID-19 cases. This handout discusses what they are, the… -
Creator: Huang, Edmund, and Stanley C. Jordan.
Subject: Research
Item Type: Publication
Date Last Updated: 2020-12-10
Description: Nearly 10 months after the identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the virus responsible for coronavirus disease 2019 (Covid-19), therapeutic options remain limited. -
Creator: WHO Solidarity Trial Consortium
Subject: Research
Item Type: Publication
Date Last Updated: 2020-12-02
Description: World Health Organization expert groups recommended mortality trials of four repurposed antiviral drugs — remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a — in patients hospitalized with coronavirus disease 2019 (Covid-19). -
Creator: NETEC
Subject: Treatment & Care
Item Type: Webinar
Date Last Updated: 2020-11-25
Description: In this webinar, we will identify important considerations involving Monoclonal Antibody Therapeutics available for emergency use authorization (EUAs) for mild-to-moderate COVID-19 cases, discuss recent criteria for the FDA approved investigational… -
Creator: Cavalcanti, Alexandre B., Fernando G. Zampieri, Regis G. Rosa, Luciano C. P. Azevedo, Viviane C. Veiga, Alvaro Avezum, Lucas P. Damiani, Aline Marcadenti, Letícia Kawano-Dourado, Thiago Lisboa, Debora L. M. Junqueira, Pedro G. M. de Barros e Silva,…
Subject: Research
Item Type: Publication
Date Last Updated: 2020-11-19
Description: Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited. -
Creator: The RECOVERY Collaborative Group
Subject: Research
Item Type: Publication
Date Last Updated: 2020-11-19
Description: Hydroxychloroquine and chloroquine have been proposed as treatments for coronavirus disease 2019 (Covid-19) on the basis of in vitro activity and data from uncontrolled studies and small, randomized trials. -
Creator: NETEC
Subject: Treatment & Care
Item Type: Webinar
Date Last Updated: 2020-11-18
Description: In this webinar, we will discuss current evidence surrounding clinical trials for COVID-19 therapeutics including ACTT1, ACTT2, and ACTT3, and describe the FDA's Coronavirus Treatment Acceleration Program (CTAP) when determining new treatments for…
